EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Forty Seven's enterprise value is $4,599.40 Mil.
Forty Seven's EBITDA for the trailing twelve months (TTM) ended in Dec. 2019 was $-86.95 Mil. Therefore, Forty Seven's EV-to-EBITDA for today is -52.90.
The historical rank and industry rank for Forty Seven's EV-to-EBITDA or its related term are showing as below:
FTSV's EV-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 9.97 * Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Forty Seven EV-to-EBITDA Historical Data
The historical data trend for Forty Seven's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Forty Seven's EV-to-EBITDA
For the Biotechnology subindustry, Forty Seven's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forty Seven's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Forty Seven's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Forty Seven's EV-to-EBITDA falls into.
Forty Seven EV-to-EBITDA Calculation
Forty Seven's EV-to-EBITDA for today is calculated as:
Forty Seven's current Enterprise Value is $4,599.40 Mil.
Forty Seven's EBITDA for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-86.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Forty Seven (NAS:FTSV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Forty Seven's PE Ratio for today is calculated as:
Forty Seven's share price for today is $95.51.
Forty Seven's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.460.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Forty Seven's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Forty Seven Inc is a clinical-stage immuno-oncology company. It is engaged in developing novel checkpoint therapies to activate macrophages and help the patients in their fight against cancer. It founded that blocking CD47, a key signaling molecule that is overexpressed on cancer cells renders tumors susceptible to macrophages. It is also preparing investigational compounds into clinical testing. FSI-174, an anti-cKIT antibody, is being developed in combination with magrolimab as a novel, all-antibody conditioning regimen to address the limitations of current stem cell transplantation conditioning regimens. FSI-189, an anti-SIRP-alpha antibody, is being developed for the treatment of cancer, and certain non-oncology conditions, including transplantation conditioning.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FTSV has been successfully added to your 